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ABSTRACT  
Purpose 
A multi-centre, randomised-controlled, open, phase IIB non-inferiority trial in previously 
untreated Chronic Lymphocytic Leukemia (CLL). Conventional frontline therapy for fit patients 
with CLL is fludarabine, cyclophosphamide and rituximab (FCR). The key assumption for 
ARCTIC was that the addition of mitoxantrone to FCR with the use of low dose rituximab 
(FCM-miniR) would be a non-inferior alternative to FCR.  
 
Patients and Methods 
206 patients were to be randomised to FCR or FCM-miniR. The primary endpoint was Complete 
Remission (CR) according to IWCLL criteria. Secondary endpoints were progression-free 
survival (PFS), overall survival (OS), overall response rate (ORR), minimal residual disease 
(MRD) eradication, safety and cost-effectiveness.  
 
Results 
200 participants were recruited from 34 UK centres. A pre-planned interim analysis led to early 
trial closure. 100 participants completed FCR, 79 FCM-miniR and 21 commenced FCM-miniR 
but crossed over to FCR following Data Monitoring Committee (DMC) recommendations. At 
final analysis, CR rates were 76% for FCR compared to 55% for FCM-miniR [adjusted odds-
ratio:0.37; 95%CI:0.19-0.73]. MRD-negativity rates were 54% for FCR compared to 44% for 
FCM-miniR. More participants experienced a Serious Adverse Reaction (SAR) with FCM-
miniR compared to FCR (49% vs. 41%). At a median of 50 months follow-up, PFS and OS 
survival were good compared to previous studies with no significant difference between the 
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treatment groups. The economic analysis indicates that FCM-miniR is not expected to be cost-
effective over a lifetime horizon. 
 
Conclusions 
FCM-miniR is less well tolerated with poorer response and MRD-negativity rates and increased 
toxicity than FCR, and therefore FCM-miniR will not be taken forward into a Phase III trial. The 
trial demonstrated that oral FCR yields extremely high response rates compared to historical 
series with intravenous chemotherapy. 
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INTRODUCTION 
Chronic lymphocytic leukemia (CLL) is the most common leukemia above the age of 50 years. 
For physically fit patients, the addition of rituximab to fludarabine and cyclophosphamide (FCR) 
has become the standard of care based on evidence from large randomised controlled trials1,2. 
However, the dose of rituximab has not been established systematically in CLL. Rituximab 
monotherapy at a dose of 375mg/m2 induced an overall response rate (ORR) of 13% in 
previously-treated CLL/small lymphocytic lymphoma (SLL)3,4. Thrice weekly rituximab 
(375mg/m2) and higher weekly doses of rituximab (0.5-2.5g/m2) in previously untreated patients 
induced a modest ORR of 43% and 40%, respectively5-7. The poor response was thought to be 
due to low CD20 expression on CLL cells and rituximab binding to CD20 positive cellular 
debris. The loss of CD20 antigen from CLL cells when exposed to rituximab (termed “antigen 
shaving”) is well described in CLL. Most of the CLL cells were cleared after 30mg of rituximab 
followed by recrudescence of CLL cells which have lost >90% of CD20 expression. Low-dose 
rituximab thrice weekly at 20-60mg/m2 may promote enhanced clearance of CLL cells by 
preserving CD20 expression8. Subcutaneous rituximab thrice weekly at a dose of 20mg resulted 
in reduction of CD20 expression on CLL cells but sufficient expression was maintained during 
the course of 6-12 weeks in another study9. Thrice weekly rituximab at 20mg/m2 in combination 
with Alemtuzumab and Pentostatin showed that this dose is able to opsonize and clear the 
majority of circulating cells, but the loss of CD20 is less pronounced10. Hence, rituximab at 
doses of 20mg/m2 can be effective in CLL.  
The combination of mitoxantrone with fludarabine and cyclophosphamide (FCM) is reported in 
60 relapsed or resistant patients with CLL11 to yield 78% ORR, 50% achieving complete 
remission (CR) and 10 patients achieving Minimal Residual Disease (MRD) negativity. A non-
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randomised Phase II trial of FCM plus rituximab (FCM-R)12 reported 82% CRs and 93% ORR in 
previously untreated CLL, with 46% achieving MRD-negativity. The NCRI randomised Phase II 
study including FCM and FCM-R in 52 previously-treated CLL patients reported CRs of 65% 
(FCM-R) versus 58% (FCM), with MRD-negativity in 5 patients (FCM-R) and 3 patients 
(FCM)13.  
The aim of the ARCTIC trial was to test the hypothesis that a low-dose of rituximab (100mg per 
cycle) in combination with FCM (FCM-miniR) would be as effective as standard of care (FCR). 
Higher doses of rituximab are required as a single agent due to the tumor burden, resulting in 
better overall response rates (ORRs). However, it is hypothesised that FCM-miniR may result in 
effective tumor clearance and preservation of CD20 expression on CLL cells.  
The cost-effectiveness of delivering FCM-miniR as an alternative to the standard therapy FCR is 
also critical. Six cycles of rituximab at a dose of 500mg/m2 are time consuming to give and 
expensive compared to low doses (100mg per cycle). The non-inferiority design of the trial helps 
to establish whether lowering the dose of rituximab and hence reducing the cost of treatment 
impacts on the efficacy in terms of CR rates, as well as the longer term progression-free survival 
(PFS) and overall survival (OS) outcomes.  
 
PATIENTS AND METHODS 
Trial Design 
ARCTIC was a multi-centre, randomised, controlled, open, phase IIB non-inferiority trial 
including patients with previously-untreated CLL who required treatment by IWCLL criteria14. 
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Patients were randomised via a central computer-generated minimisation program incorporating 
a random element 1:1 to FCR or FCM-miniR. Randomisation was stratified to ensure balance for 
centre, Binet Stage (Progressive A or B, C), age group (≤65, 65) and sex. 
The primary objective was to assess whether FCM-miniR was non-inferior to FCR in terms of 
CR rates, including CR with incomplete marrow recovery (CRi), in patients with previously 
untreated CLL. The results would be used to determine whether FCM-miniR should be taken 
forward into a larger definitive Phase III trial. 
An independent Data Monitoring Committee (DMC) was established to review the safety and 
ethics of the trial. The DMC reviewed unblinded safety data on a six-monthly basis and 
unblinded safety and trial progress reports on an annual basis. There was a pre-planned interim 
assessment of efficacy on half the required number of participants. The DMC reported to an 
established trial steering committee (TSC) who provided general oversight for the trial. 
The trial was approved by the National Research Ethics Service Leeds (East) Research Ethics 
Committee. The trial was registered as an International Standard Randomised Controlled Trial 
(ISRCTN16544962) and on the European Clinical Trials Database (EudraCT:2009-010998-20). 
Patients 
The intention was to include 206 patients from ethically approved hospitals around the United 
Kingdom (UK). Eligible participants had progressive CLL requiring treatment by IWCLL 
criteria14; no prior treatment for CLL; WHO performance status 0-2; Binet Stage progressive A, 
B or C; and had provided written consent. Patients with Hepatitis B or C; an active secondary 
malignancy (excluding basal cell carcinoma); an active infection or a past history of anaphylaxis 
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following exposure to rat or mouse-derived complementarity determining region (CDR)-grafted 
humanized monoclonal antibody were not eligible. Patients with creatinine clearance greater than 
30ml/min were allowed with guidance on dose reduction for fludarabine. Participants were able 
to withdraw from the trial at any time. 
Treatment and assessments 
Treatment with FCR or FCM-miniR was repeated every 28 days for a total of six cycles. 
Fludarabine and cyclophosphamide were administered orally at doses of 24mg/m2/day and 
150mg/m2/day for first five days of each cycle respectively. Full dose rituximab was 
administered intravenously at 375mg/m2 on day 1 of cycle 1 and 500mg/m2 in cycles 2-6. In 
participants with lymphocyte counts greater than 25x109/L, the dose of rituximab was split to 
100mg on day 1 with remaining rituximab given on day 2 to reduce the risk of infusion related 
reactions. Participants unable to tolerate oral chemotherapy were permitted to receive equivalent 
intravenous doses of fludarabine (25mg/m2/day for 3 days) and cyclophosphamide 
(250mg/m2/day for 3 days). FCM-miniR included intravenous mitoxantrone (6mg/m2/day) and 
100mg rituximab on day 1 of each cycle. Participants with neutropenia delaying therapy received 
G-CSF (lenograstim 263mcg/day; days 7-13) on all remaining cycles. All participants were 
given allopurinol at least in cycle 1. PCP prophylaxis and acyclovir were given throughout the 
treatment. Secondary prophylaxis with G-CSF was recommended with delays of therapy due to 
neutropenia and appropriate dose reductions were recommended in response to cytopenias. 
Participants were followed up for response to treatment at 3 months post-treatment, 12, 18 and 
24 months post-randomisation or until disease progression requiring treatment, and for survival 
until death. 
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Endpoints 
The primary endpoint was CR rate at three months post-treatment. Response was centrally 
assessed according to IWCLL criteria14 by two independent, experienced CLL haematologists 
blinded to treatment allocation. An independent arbiter reviewed discordant reports.  
Secondary endpoints at three months post-treatment included MRD eradication, assessed in the 
bone marrow by highly sensitive multiparameter flow cytometry with a level of detection below 
1 CLL cell in 10000 leukocytes15; ORR defined as at least a partial remission (PR); and safety 
and toxicity as graded by CTCAE V3.0. 
Longer-term secondary endpoints included PFS, OS, time to MRD relapse in participants who 
became MRD-negative, and cost-effectiveness.  
An economic evaluation was conducted from a National Health Service (NHS) and Personal 
Social Services (PSS) perspective, with health benefit measured in Quality-Adjusted Life-Years 
(QALYs) (estimated from the EQ-5D questionnaires)16. A within-trial analysis compared the 
outcomes and costs over 24 months, and a modified Markov model was used to estimate lifetime 
cost-effectiveness.  
Sample size 
Previous studies showed FCR CR rates of at least 50%17,18. With 80% power to show non-
inferiority, where this is defined as FCM-miniR being not more than 10% worse in terms of CR 
rates than FCR, an assumed 10% difference in favour of FCM-miniR, a 1-sided significance 
level (α) of 2.5%19 and 80% power, 98 patients were required per group. 206 patients were 
planned, allowing for 5% dropout.   
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A formal interim analysis to allow large differences between the treatment groups to be reported 
early was planned on the short-term efficacy data on half the required participants (n=103). A 
stringent significance level was required for the interim analysis (0.005, 2-sided) using the 
O’Brien-Fleming20 alpha-spending function. 
Statistical methods 
All analyses were conducted on the intention-to-treat (ITT) population, in which participants 
were included according to their randomised treatment. A per-protocol analysis was planned for 
the primary endpoint, including participants who received at least one cycle of treatment as 
protocolled and were not major eligibility violators. Safety and toxicity analyses included 
participants according to the treatment they actually received. 
Methods for handling missing endpoint data were pre-specified and approved by the Chief 
Investigator. Participants with a missing assessment who died from CLL or protocol treatment or 
discontinued treatment early due to non-response or toxicity were treated as non-
responders/MRD-positive. In the formal primary analysis, for participants with at least a PR but 
missing trephine data to confirm a CR, imputation methods treated MRD-negative participants as 
having a CR and MRD-positive as not. Participants without an available endpoint assessment 
were excluded. This was appropriate as it can be assumed that data are missing completely at 
random (MCAR), since assessments were most likely unavailable due to samples being un-
assessable or missed in error, rather than participant refusal due to level of response or treatment 
allocation.  
Binary logistic regression models compare CR rates, proportions with undetectable MRD and ORR 
between the treatment groups, adjusting for the minimisation factors, excluding centre. The 
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differences in proportions are reported with 95% confidence intervals (CIs). The lower limit of the 
CI for the CR rates is compared with the non-inferiority margin of 10%, expressed as an odds 
ratio (OR). 
Cox regression analysis formally compares time to MRD relapse, PFS and OS. Participants 
without evidence of an event at the time of analysis are censored at the last date they were known 
to be alive and event-free. Kaplan-Meier curves are presented. 
Safety analyses summarise the number of safety events occurring after randomisation including 
treatment-related mortalities and incidence of secondary cancers.  
The economic evaluation uses a within trial analysis, in which cost-effectiveness is assessed 
within the 24-month trial period using individual patient data collected in the trial; and a decision 
analytic model analysis, in which cost-effectiveness is assessed over a lifetime horizon using 
standard modelling techniques applied to the trial data in order to extrapolate the trial results.  
Sensitivity analyses assess the robustness of the assumptions regarding missing primary endpoint 
data.  
 
RESULTS 
Recruitment and Early Closure 
200 participants were randomised between December 2009-September 2012 (FCR:100, FCM-
miniR:100) from 34 UK institutions with local ethical and management approval. The 
CONSORT diagram (Figure 1) shows the flow of participants throughout the trial. 
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The trial closed early in September 2012 following recommendation from the DMC and TSC. At 
the pre-planned interim analysis on 103 participants, CR rates were 82.9% for FCR compared to 
61.4% for FCM-miniR, difference -21.6%(99.5%CI:-48.0%,4.8%), adjusted p=0.037. Although 
not significant at the pre-planned interim level (α=0.005), the results approached significance in 
favour of FCR. There was also evidence of additional toxicity in the FCM-miniR group. The 
DMC recommended ceasing recruitment immediately; with participants receiving FCM-miniR 
recommended to transfer to FCR for the remainder of their treatment cycles. 21/23 FCM-miniR 
participants transferred to receive treatment with FCR (labelled FCM-miniR/FCR) following 
discussion with their treating clinician, two from cycle one. 
Patient Characteristics 
Baseline characteristics are displayed in Table 1. The median age was 63 years (range 36–80) 
with 75(37.5%) aged >65 years. There was a male predominance 135(67.5%), and 34(17.0%) 
were Binet Stage progressive A, 95(47.5%) stage B and 71(35.5%) stage C. 116(58.0%), 
77(38.5%) and 7(3.5%) were WHO performance status 0, 1 and 2 respectively. 103(51.5%) had 
B-symptoms, a higher proportion with FCM-miniR [FCR:46(46.0%), FCM-miniR:57(57.0%)]. 
115(57.5%) had β2-microglobulin ≥4mg/L, whilst 31(15.5%) had creatinine clearance of 30-
60mls/min. Of the evaluable patients, 7/183(3.8%) were 17p-deleted (FCR:4, FCM-miniR:3); 
30/188(16.0%) were 11q-deleted (FCR:10, FCM-miniR:20) and 104/165(63.0%)  were 
considered to be ‘poor risk’ in terms of VH mutation status. 
Treatment 
Of the 200 participants, 141(70.5%) received 6 cycles of treatment [FCR:70(70.0%), FCM-
miniR:51(64.5%), FCM-miniR/FCR:20(95.2%)] and 31(15.5%) received ≤3cycles of treatment 
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[FCR:15(15.0%), FCM-miniR:16(20.3%), FCM-miniR/FCR:0(0.0%)](Table 2). Two FCR 
participants did not receive any trial treatment, one had received prior therapy for CLL, and one 
was 17p deleted and withdrawn from the trial. 59(29.5%) discontinued treatment early 
[FCR:30(30.0%), FCM-miniR:28(35.4%), FCM-miniR/FCR:1(4.8%)]. Reasons were: 
toxicity(n=44); progressive disease(n=3); stable disease with no or minimal response(n=3); 
ineligibility(n=1), patient choice(n=3); clinician decision(n=4); other(n=1). 94(47.0%) received 
G-CSF during treatment as planned in the protocol as secondary prophylaxis, with a higher 
proportion of those receiving FCM-miniR [FCR:42(42.0%), FCM-miniR:40(50.6%)](Table 2). 
Efficacy 
Of the 200 patients, 124(62.0%) achieved a CR [FCR: 68(68.0%), FCM-miniR:39(49.4%), 
FCM-miniR/FCR:17(81.0%)].   In the formal analysis of the primary endpoint including 
imputation based on MRD outcome [based on 167 participants: FCR:92(92.0%), FCM-
miniR:75(75.0%)], 66.5%(n=111) achieved a CR, [FCR:70(76.1%),  FCM-miniR:41(54.7%)], 
with difference -21.4% in favour of FCR (95%CI:-35.8%,-7.0%). The OR for achieving a CR 
with FCM-miniR compared to FCR was 0.37(95%CI:0.19,0.73) (Table 3). A 10% non-
inferiority reduction from the FCR CR rate gives an OR limit of 0.61. Since the lower limit, and 
in fact the mean, of the 95% CI for the treatment effect  is less than 0.61, and the upper limit is 
below 1, there is evidence that FCM-miniR is significantly inferior to FCR. The per-protocol 
analysis(n=166) concurred with the outcome of the ITT analysis, OR=0.38(95%CI:0.19,0.75). 
The sensitivity analyses did not affect the findings.  
There were no large differences in proportions achieving a CR by sex [Males:65.0%, 
Females:70.0%], age group [≤65:70.8%, >65:59.0%], or Binet stage [A progressive/B:68.5%, 
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C:62.5%]. A significantly higher proportion who received >3cycles of treatment achieved a CR 
[≤3cycles:28.0%, >3cycles:73.2%], difference[-45.2%(95%CI:-64.3%,-26.2%)]. 
All assessable 17p deleted participants failed to achieve a CR(n=6). Lower proportions of 11q 
deleted and poor risk VH mutated participants achieved a CR [11qdel:58.3%, not-
11qdel:67.7%], [VHPoor:62.1%, VHStandard:69.2%]. 
The ORR was 92.6%(163/176) with a higher proportion achieving at least a PR with FCR than 
FCM-miniR [FCR:94/98(95.9%), FCM-miniR:69/78(88.5%), 95%CI for difference:(-
15.6%,0.6%)].  
Of the 200 patients, 85(42.5%) achieved MRD-negativity [FCR: 45(45.0%), FCM-
miniR:29(36.7%), FCM-miniR/FCR:11(52.4%)].  There was a non-significant trend towards 
FCM-miniR resulting in lower MRD-negativity rates at three months post-treatment 
[FCR:45/83(54.2%), FCM-miniR:29/66(43.9%), difference:-10.3%(95%CI:-26.3%,5.8%), 
adjusted OR:0.65(95%CI:0.33,1.26)](Table 3).  
The median follow-up for survivors is 50 months (range:36-70). 33(16.5%) participants have 
died [FCR:14(14.0%), FCM-miniR:18(22.8%), FCM-miniR/FCR:1(4.8%)] and 73(36.5%) 
progressed or died [FCR:34(34.0%), FCM-miniR:35(44.3%), FCM-miniR/FCR:4(19.0%)]. 
Figure 2 presents the PFS and OS Kaplan-Meier curves by treatment group (excluding FCM-
miniR/FCR). At 36 months post-randomisation, the PFS rate is FCR:75.3%, FCM-miniR:71.3%; 
with OS rate FCR:89.1%, FCM-miniR:84.3%.  The hazard ratios (HR) were not significant in 
the adjusted Cox regression model [PFS: HR=1.29, 95%CI:(0.80,2.07), p=0.298; OS: HR=1.62, 
95%CI:(0.80, 3.28), p=0.178]. Note the relatively short follow-up leading to a high number of 
censored observations.  
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Of the 85 participants who were MRD-negative in the bone marrow at three months post-
treatment(Table 3), only 9(10.6%) participants have relapsed at the MRD level in the peripheral 
blood or progressed (FCR:5, FCM-miniR:4).  
Kaplan-Meier curves demonstrated an improved PFS in participants who achieved a CR or 
MRD-negativity at 3 months post-treatment(Figure 3). There was a trend towards participants 
with a standard VH mutation risk showing an improved PFS over those with poor risk, but no 
evidence of a difference for 11q deletion status(Figure3). Subgroup analyses for OS show 
similar trends.  
Cost-effectiveness 
Over the planned 24-month trial period, FCM-miniR produced a mean cost saving of 
£6,619(s.d.£1,061), and QALY loss of -0.059(s.d.0.06) compared to FCR. Assuming that one 
QALY is valued at £20,000, FCM-miniR is cost-effective over the trial period, producing a 
positive incremental net health benefit (+0.27 QALYs; s.d.0.08). However, FCM-miniR is not 
expected to be cost-effective over a lifetime horizon, with an expected lifetime cost-saving of 
£7,723(s.d.£3,281), and QALY loss of -0.73(s.d.0.42), resulting in an incremental net health loss 
(QALY:-0.34;s.d.0.40)(Table 4).  
Safety and Toxicity 
The safety population included 198 participants(Figure 1). 145 Serious Adverse Reactions 
(SARs) were reported from 89(44.9%) participants [FCR:62 events from 41(41.0%); FCM-
miniR:67 events from 39(49.4%); FCM-miniR/FCR:16 events from 9(47.4%)]. A further 38 
Serious Adverse Events (SAEs) were not suspected to be related to trial treatment.  
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One Suspected Unexpected Serious Adverse Reaction (SUSAR) was reported in the FCR group. 
A squamous cell carcinoma, two lesions on the lower back and central chest was diagnosed 
approximately 4 months after six cycles of treatment.  
Adverse Events (AE) were reported from 192(97.0%) participants. Of the 2163 AEs reported, 
388(17.9%) were graded as CTCAE grade 3 or above [FCR:168(15.0%); FCM-
miniR:193(22.4%); FCM-miniR/FCR:27(14.8%)].  
There were no treatment-related mortalities reported within 3 months of the end of protocol 
treatment.  
Within 3 years following treatment, 26(13.1%) participants had been diagnosed with a secondary 
cancer [FCR:13(13.0%); FCM-miniR:12(15.2%); FCM-miniR/FCR:1(5.3%)]. The most 
common type being skin (non-melanoma) 13(6.6%) followed by haematological (AML/MDS) 
7(3.5%).  
 
DISCUSSION 
Participants randomised to FCM-miniR had a significantly lower CR rate than those randomised 
to FCR (54.7% vs. 76.1%), indicating the FCR is the more effective treatment. This seems, at 
least in part, due to the higher toxicity associated with the addition of mitoxantrone to FCR. Key 
secondary endpoints were consistent in demonstrating that FCR has greater efficacy, with a 
higher proportion of participants achieving eradication of MRD (FCR:54.2%, FCM-
miniR:43.9%). The follow-up in the trial is still relatively immature (median 50 months from 
randomisation) but to date the PFS and OS are good compared to previous studies, and there is 
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no significant difference between the treatment groups, although there is a trend towards 
improved survival for FCR participants.  
The cost-effectiveness analysis indicates that whilst FCM-miniR is expected to be cost-effective 
in the short term, it is unlikely to be cost-effective when taking into account long term costs and 
health benefits, although there is significant uncertainty around the long term results.  
In summary, we demonstrate that FCM-miniR is not non-inferior to FCR in terms of the primary 
end-point of CR at 3-months post-treatment. In addition FCM-miniR shows evidence of reduced 
efficacy in terms of MRD and survival, had increased toxicity, and is not cost-effective longer 
term. In view of this, FCM-miniR will not be taken forward into a larger definitive Phase III 
trial.  
The trial demonstrated that oral FCR yields extremely high response and MRD eradication rates 
compared to historical series in which the chemotherapy was given intravenously, and remains 
the gold-standard therapy for CLL in participants considered fit for fludarabine-based therapy. 
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SUPPLEMENTARY MATERIAL 
Trial Protocol 
The ARCTIC trial protocol can be accessed from the NIHR website: 
http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0016/51721/PRO-07-01-38.pdf 
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FIGURES 
Figure 1 CONSORT Diagram 
  
Analysis populations: 
Intention-to-treat (n=92): 
- Excluded from ITT analysis (n=8): 
o Missing primary endpoint data (n=8) 
 
Per-protocol (n=91): 
- Excluded from PP analysis (n=9): 
o Missing primary endpoint data (n=8a) 
o Did not receive any FCR (n=1a) 
o Breach of eligibility criteria (prior therapy for CLL) and did not 
receive any FCR (n=1) 
 
Safety population (n=100): 
- Excludes 2 FCR participants who failed to receive any treatment 
- Includes 2 FCM-miniR participants who received FCR from cycle 1 
 
a One participant did not receive any FCR and also had missing primary 
endpoint data and is therefore recorded twice 
 
Analysis populations: 
Intention-to-treat (n=75): 
- Excluded from ITT analysis (n=25): 
o Missing primary endpoint data (n=5b) 
o Received FCR (n=21b) 
 
 Per-protocol (n=75): 
- Excluded from PP analysis (n=25): 
o Missing primary endpoint data (n=5b) 
o Received FCR (n=21b) 
 
 
Safety population (n=98): 
- FCM-miniR (n=79) 
- FCM-miniR/FCR (n=19) 
b One participant received FCR and had missing primary endpoint data 
and is therefore recorded twice 
Assessed for eligibility (n=548) 
Excluded (n=348) 
- Patient clinically ineligible (n=228) 
- Patient did not wish to participate (n=39) 
- Patient too ill to participate (n=4) 
- Other reason (n=77) 
Withdrawn consent from trial (n=5): 
- From trial treatment only (n=1) 
- From trial treatment and follow-up data collection (n=4) 
 
Post-randomisation ineligibility (n=2): 
- Prior therapy for CLL (n=1) 
- Active or prior Hepatitis B or C (n=1) 
 
 Lost to follow-up: missing primary endpoint data (n=8): 
- Missing trephine sample (n=6) 
- Withdrew from follow-up data collection prior to assessment of 
primary endpoint (n=2) 
 
Allocated to FCR (n=100): 
 
Received FCR throughout the trial (n=98) 
Did not receive any FCR (n=2): 
- Clinical decision due to 17p deletion (n=1)  
- Breach of eligibility criteria, prior therapy for CLL (n=1) 
 
Withdrawn consent from trial (n=4): 
- From trial treatment only (n=1) 
- From trial treatment and follow-up data collection (n=2) 
- From follow-up data collection only (n=1) 
Post-randomisation ineligibility (n=0) 
 
Lost to follow-up: missing primary endpoint data: (n=5) 
- Missing trephine sample (n=4) 
- Unable to assess due to insufficient clinical evaluations performed 
at 3 month post-treatment visit (n=1) 
 
Allocated to FCM-miniR (n=100): 
Received FCM-miniR throughout the trial (n=79) 
Commenced FCM-miniR but transferred over to FCR as a result of the 
interim analysis (n=19) 
Did not receive any FCM-miniR (n=2): 
- Received FCR from cycle one as a result of the interim analysis 
(n=2) 
        
Randomised (n=200) 
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Table 1 Baseline Characteristics 
 FCR (n=100) 
FCM-miniR 
(n=100) 
Total 
(n=200) 
Age (at randomisation)    
≤65 63 (63.0%) 62 (62.0%) 125 (62.5%) 
>65 37 (37.0%) 38 (38.0%) 75 (37.5%) 
Mean (s.d.) 61.8 (8.3) 62.6 (8.3) 62.2 (8.3) 
Median (range) 63 (41, 77) 63 (36, 80) 63 (36, 80) 
Sex    
Male 68 (68.0%) 67 (67.0%) 135 (67.5%) 
Female 32 (32.0%) 33 (33.0%) 65 (32.5%) 
Binet Stage    
Progressive A 20 (20.0%) 14 (14.0%) 34 (17.0%) 
B 41 (41.0%) 54 (54.0%) 95 (47.5%) 
C 39 (39.0%) 32 (32.0%) 71 (35.5%) 
B-symptoms    
Yes 46 (46.0%) 57 (57.0%) 103 (51.5%) 
No 54 (54.0%) 43 (43.0%) 97 (48.5%) 
WHO performance status    
0 55 (55.0%) 61 (61.0%) 116 (58.0%) 
1 40 (40.0%) 37 (37.0%) 77 (38.5%) 
2 5 (5.0%) 2 (2.0%) 7 (3.5%) 
Beta-2 microglobulin concentration (mg/L)    
<4 mg/L 37 (37.0%) 35 (35.0%) 72 (36.0%) 
≥4 mg/L 53 (53.0%) 62 (62.0%) 115 (57.5%) 
Missing 10 (10.0%) 3 (3.0%) 13 (6.5%) 
Creatinine clearance (mls/min)    
30-60mls/min 17 (17.0%) 14 (14.0%) 31 (15.5%) 
>60mls/min 83 (83.0%) 86 (86.0%) 169 (84.5%) 
17p deleted    
Yes (poorer risk) 4 (4.0%) 3 (3.0%) 7 (3.5%) 
No (standard risk) 88 (88.0%) 88 (88.0%) 176 (88.0%) 
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 FCR (n=100) 
FCM-miniR 
(n=100) 
Total 
(n=200) 
Missing 8 (8.0%) 9 (9.0%) 17 (8.5%) 
11q deleted    
Yes (poorer risk) 10 (10.0%) 20 (20.0%) 30 (15.0%) 
No (standard risk) 83 (83.0%) 75 (75.0%) 158 (79.0%) 
Missing 7 (7.0%) 5 (5.0%) 12 (6.0%) 
VH mutation risk status*    
Poor risk 52 (52.0%) 52 (52.0%) 104 (52.0%) 
Standard risk 30 (30.0%) 31 (31.0%) 61 (30.5%) 
Missing 18 (18.0%) 17 (17.0%) 35 (17.5%) 
*Poor risk - VH unmutated, or involving the VH3-21 gene; Standard risk - VH mutated and not involving 
the VH3-21 gene 
WHO: World Health Organisation 
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Table 2 Treatment Summaries 
 FCR (n=100) 
FCM-miniR 
(n=79) 
FCM-miniR/FCR 
(n=21) 
Total 
(n=200) 
Discontinued treatment 
early (received <6 cycles)?     
Yes 30 (30.0%) 28 (35.4%) 1 (4.8%) 59 (29.5%) 
No 70 (70.0%) 51 (64.5%) 20 (95.2%) 141 (70.5%) 
Treatment cycles received     
≤ 3 cycles 15 (15.0%) 16 (20.3%) 0 (0.0%) 31 (15.5%) 
> 3 cycles 85 (85.0%) 63 (79.7%) 21 (100.0%) 169 (84.5%) 
Received G-CSF during 
treatment (cycles 2 - 6)?     
Yes 42 (42.0%) 40 (50.6%) 12 (57.1%) 94 (47.0%) 
No 53 (53.0%) 34 (43.0%) 9 (42.9%) 96 (48.0%) 
Unknown 5 (5.0%) 5 (6.3%) 0 (0.0%) 10 (5.0%) 
G-CSF: Granulocyte-colony stimulating factor was given if there was significant neutropenia on a 
previous cycle of treatment 
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Table 3 Efficacy Summaries 
CR status (prior to 
imputation using MRD) 
FCR 
(n=100) 
FCM-miniR 
(n=79) 
FCM-miniR/FCR 
(n=21) 
Total 
(n=200) 
Achieved a CR 68 (68.0%) 39 (49.4%) 17 (81.0%) 124 (62.0%) 
Did not achieve a CR 18 (18.0%) 28 (35.4%) 3 (14.3%) 49 (24.5%) 
Missing 14 (14.0%) 12 (15.2%) 1 (4.8%) 27 (13.5%) 
CR status (post 
imputation using MRD) 
FCR 
(n=100) 
FCM-miniR 
(n=79) 
FCM-miniR/FCR 
(n=21) 
Total 
(n=200) 
Achieved a CR 70 (70.0%) 41 (51.9%) 17 (81.0%) 128 (64.0%) 
Did not achieve a CR 22 (22.0%) 34 (43.0%) 3 (14.3%) 59 (29.5%) 
Missing 8 (8.0%) 4 (5.1%) 1 (4.8%) 13 (6.5%) 
Achievement of the 
primary endpoint  
FCR 
(n=92) 
FCM-miniR 
(n=75) 
Total 
(n=167) 
Difference in CR rates 
& 95% CIs 
(FCM-miniR - FCR) 
Achieved a CR 70 (76.1%) 41 (54.7%) 111 (66.5%) -21.4% (-35.8%, -7.0%) 
Did not achieve a CR 22 (23.9%) 34 (45.3%) 56 (33.5%)  
Logistic regression analysis for the % of participants achieving a CR 
Parameter* Parameter estimate SE OR 95% CIs for OR 
FCM-miniR vs. FCR -0.98 0.34 0.37 (0.19, 0.73) 
MRD status 
FCR 
(n=100) 
FCM-miniR 
(n=79) 
FCM-miniR/FCR 
(n=21) 
Total 
(n=200) 
MRD negative 45 (45.0%) 29 (36.7%) 11 (52.4%) 85 (42.5%) 
MRD positive 38 (38.0%) 37 (46.8%) 9 (42.9%) 84 (42.0%) 
Missing 17 (17.0%) 13 (16.5%) 1 (4.8%) 31 (15.5%) 
MRD status 
 
FCR 
(n=83) 
 
FCM-miniR 
(n=66) 
Total 
(n=149) 
Difference in MRD-
negative rates 
& 95% CIs 
(FCM-miniR - FCR) 
MRD negative 45 (54.2%) 29 (43.9%) 74 (49.7%) -10.3 (-26.3,  5.8) 
MRD positive 38 (45.8%) 37 (56.1%) 75 (50.3%)  
Logistic regression analysis for the % of participants achieving MRD-negativity  
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CR status (prior to 
imputation using MRD) 
FCR 
(n=100) 
FCM-miniR 
(n=79) 
FCM-miniR/FCR 
(n=21) 
Total 
(n=200) 
Achieved a CR 68 (68.0%) 39 (49.4%) 17 (81.0%) 124 (62.0%) 
Did not achieve a CR 18 (18.0%) 28 (35.4%) 3 (14.3%) 49 (24.5%) 
Missing 14 (14.0%) 12 (15.2%) 1 (4.8%) 27 (13.5%) 
CR status (post 
imputation using MRD) 
FCR 
(n=100) 
FCM-miniR 
(n=79) 
FCM-miniR/FCR 
(n=21) 
Total 
(n=200) 
Achieved a CR 70 (70.0%) 41 (51.9%) 17 (81.0%) 128 (64.0%) 
Did not achieve a CR 22 (22.0%) 34 (43.0%) 3 (14.3%) 59 (29.5%) 
Missing 8 (8.0%) 4 (5.1%) 1 (4.8%) 13 (6.5%) 
Achievement of the 
primary endpoint  
FCR 
(n=92) 
FCM-miniR 
(n=75) 
Total 
(n=167) 
Difference in CR rates 
& 95% CIs 
(FCM-miniR - FCR) 
Achieved a CR 70 (76.1%) 41 (54.7%) 111 (66.5%) -21.4% (-35.8%, -7.0%) 
Did not achieve a CR 22 (23.9%) 34 (45.3%) 56 (33.5%)  
Logistic regression analysis for the % of participants achieving a CR 
Parameter* Parameter estimate SE OR 95% CIs for OR 
FCM-miniR vs. FCR -0.98 0.34 0.37 (0.19, 0.73) 
MRD status 
FCR 
(n=100) 
FCM-miniR 
(n=79) 
FCM-miniR/FCR 
(n=21) 
Total 
(n=200) 
Parameter* Parameter estimate SE OR 95% CIs for OR 
FCM-miniR vs. FCR -0.44 0.34 0.65 (0.33, 1.26) 
CR: Complete remission (CR/CRi) 
MRD: Minimal Residual Disease 
SE: Standard error  
OR: Odds ratio 
*Adjusted estimate of the treatment effect from the multivariable logistic regression model, adjusted for the 
minimisation factors 
 
Table 4 Cost-Effectiveness Results (NHS and PSS perspective) 
Strategy 
Total Cost 
(sd) 
Total QALY 
(sd) 
Inc. 
Cost 
(sd) 
Inc. QALY 
(sd) 
ICER 
INB (QALYs)  
(sd) 
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Within-trial analysis (24-month horizon) 
FCR 
£17,241 
(745) 
1.610 
(0.04)     
FCM- miniR 
£10,622 
(758) 
1.551 
(0.05) 
-£6,619 
(1,061) 
-0.059 
(0.06) 
£112,193* 
0.27  
(0.08) 
Decision model analysis (Lifetime horizon) 
FCR 
£31,314 
(7,237) 
7.76 
(0.26)     
FCM- miniR 
£23,590 
(6,997) 
7.04 
(0.36) 
-£7,723 
(3,281) 
-0.73 
(0.42) 
£10,651* 
-0.34 
 (0.40) 
NHS: National Health Service 
PSS: Personal and Social Services 
QALY: Quality-Adjusted Life-Years 
ICER: Incremental Cost-Effectiveness Ratio 
INB: Incremental Net Benefit 
*Pounds saved per QALY lost 
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Figure 2 Kaplan Meier Curves for Progression-Free and Overall Survival 
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Figure 3 Kaplan Meier Curves for Subgroup Analyses for PFS  
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